In a report released today, Kostas Biliouris from BMO Capital downgraded Jasper Therapeutics to a Hold, with a price target of $4.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kostas Biliouris has given his Hold rating due to a combination of factors surrounding Jasper Therapeutics. The recent updates on Briquilimab’s clinical trial results, particularly in the context of chronic spontaneous urticaria (CSU), have introduced significant uncertainties. The data, while somewhat promising, is clouded by potential manufacturing issues and questions about the drug’s efficacy and safety profile, especially concerning specific product lots.
Furthermore, the competitive landscape and market conditions add to the complexity. Jasper Therapeutics faces challenges such as financing concerns and development delays compared to competitors. These factors contribute to a cautious outlook, leading to a Hold rating as investors may remain hesitant until clearer results and resolutions to these uncertainties are presented.